[Expression of tumor necrosis factor receptor on peripheral blood mononuclear cells from patients with primary hepatocellular carcinoma and effects of treatment on the expression].
OBJECTIVE
To conduct an intensive investigation of the abnormal immune status of patients with primary hepatocellular carcinoma and explore the possible mechanism of biotherapy for these patients.


METHODS
The expression of tumor necrosis factor receptor (TNFR)I and TNFR II on peripheral blood mononuclear cells (PBMCs) obtained from 30 normal subjects and 31 patients with primary hepatocellular carcinoma were examined by flow cytometry and S-P staining assay. The effects of biotherapy and chemotherapy administered in the patients were also investigated in terms of the changes in the expressions.


RESULTS
The TNFR I and TNFR II expressions in the patients were (28.35+/-9.09) % and (37.45+/-9.51) % respectively, significantly lower than those of normal subjects [(38.54+/-8.51) % and (44.89+/-9.08) %]. The biotherapy for the patients caused an increase of TNFR I expression to (42.86+/-9.02)%.


CONCLUSIONS
There are significant immune abnormalities in patients with primary hepatocellular carcinoma, and this study may offer some theoretical basis for the implementation of biotherapy in such cases.
Bai
Lan
L
Institute for Digestive Diseases of PLA, Nanfang hospital, First Military Medical University, Guangzhou 510515, China.
Huang
Chong-Wu
CW
Gao
Lei
L
Jiang
Bo
B
Nan
Qing-Zhen
QZ
D000328:Adult; D015703:Antigens, CD / Q000096:biosynthesis* / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008113:Liver Neoplasms / Q000097:blood* / Q000188:drug therapy; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000096:biosynthesis* / Q000097:blood; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha
D015703:Antigens, CD; D000970:Antineoplastic Agents; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha